Note: This is an IPO of 13.095 million American Depositary Shares (ADS). Each ADS represents one ordinary share.
We are an artificial intelligence-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Our goal is to change the pharmaceutical industry’s underlying pharmacoeconomic model, what we call “Shifting the Curve,” by improving the probability of success, time and cost involved with creating new medicines. Our drug candidate pipeline is focused on oncology, including specific deep tumors, as well as on inflammatory diseases, OCD (obsessive-compulsive disorder) and Alzheimer’s disease psychosis. This drug pipeline includes drug candidates that we wholly own and drug candidates that are being developed by our collaboration partner.
Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates. We have built a complete end-to-end solution of artificial intelligence, or AI, and experimental technologies for target identification, drug candidate design, translational models and patient selection. Our platform has enabled us to design candidate drug molecules that have progressed into clinical trials as well as to provide patients with potentially more applicable drug therapies through AI-guided assessment.
We originated the first three AI-designed precision drug candidates to enter human clinical trials. Among these is our most advanced internally developed drug candidate, EXS21546. We began the first Phase 1 clinical trial of this drug candidate in December 2020 and currently expect to report topline data from this trial by the end of 2022. The other two drug candidates, also currently in Phase 1 clinical trials, are being developed by our collaboration partner, Sumitomo Dainippon Pharma Co., Ltd., or Sumitomo Dainippon Pharma, which has sole economic rights to these drug candidates. We have designed four additional drug candidates currently undergoing advanced profiling for submission of investigational new drug, or IND, applications and have more than 25 active projects in total. Although we and our collaboration partners have to date not received regulatory approval for any of our drug candidates, we believe that the quality of our molecules has been demonstrated by the partnership expansions and product-licensing arrangements we have entered into with our collaborators, including Bristol Myers Squibb, Sanofi S.A., Sumitomo Dainippon Pharma, EQRx, Inc. and the Bill & Melinda Gates Foundation (aka the Gates Foundation).
As of June 30, 2021, we have raised an aggregate of £273.9 million ($378.6 million) through private placements of our ordinary and preferred shares.
(Note: Exscientia plc upsized its IPO at pricing on Sept. 30, 2021, to price the deal at $22 – the top of its $20-to-$22 price range – and increased the number of shares to 13.85 million ADS – up from 13.095 million ADS in the prospectus – to raise $304.7 million.)
|Address||The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom|
|Phone Number||+44 (0) 1865 818941|
|View Prospectus:||Exscientia plc|
|Revenues||$14.55 mil (last 12 months)|
|Net Income||$-54.14 mil (last 12 months)|
|Price range||$22.00 - $22.00|
|Est. $ Volume||$304.7 mil|
|Manager / Joint Managers||Goldman Sachs/ Morgan Stanley/ BofA Securities/ Barclays|
|Expected To Trade:||10/1/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|